# Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

> **NCT04842877** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 141 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Valemetostat tosylate

## Key facts

- **NCT ID:** NCT04842877
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-11
- **Primary completion:** 2024-12-03
- **Final completion:** 2026-10
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842877, "Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04842877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*